Drug reference

mobocertinib

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 907

Overview

Names and pronunciation

(moe-boe-SER-ti-nib) Exkivity

PDF page 907

Functional class

Func. class.: Antineoplastic, kinase inhibitor

PDF page 907

Uses

USES: Epidermal growth factor recep- tor (EGFR) exon 20 insertion mutation– positive metastatic non–small cell lung cancer

PDF page 907

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES • Adult: PO 160 mg daily until disease progression or unacceptable toxicity

PDF page 907

Available forms

Available forms: Tabs 40 mg

PDF page 907

Dose text by age group

Adult

• Adult: PO 160 mg daily until disease progression or unacceptable toxicity

PDF page 907

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

mobocertinib

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 907

Overview

Names and pronunciation

(moe-boe-SER-ti-nib) Exkivity

PDF page 907

Functional class

Func. class.: Antineoplastic, kinase inhibitor

PDF page 907

Uses

USES: Epidermal growth factor recep- tor (EGFR) exon 20 insertion mutation– positive metastatic non–small cell lung cancer

PDF page 907

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES • Adult: PO 160 mg daily until disease progression or unacceptable toxicity

PDF page 907

Available forms

Available forms: Tabs 40 mg

PDF page 907

Dose text by age group

Adult

• Adult: PO 160 mg daily until disease progression or unacceptable toxicity

PDF page 907

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.